Implications of cancer-associated systemic inflammation for biomarker studies

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 2, 2010, Pages 163-171

  Kowalewska, Magdalena ^a   Nowak, Radoslawa ^a   Chechlinska, Magdalena ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cancer biomarker; CTC; Inflammation; Marker specificity; Marker validation

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKINE; NUCLEIC ACID; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER; BIOLOGICAL MARKER; MOLECULAR MARKER;

BIOMICS; BLOOD ANALYSIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FATTY ACID ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEIC ACID ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; SYSTEMIC DISEASE; T LYMPHOCYTE; BLOOD EXAMINATION; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; METABOLOMICS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR MICROENVIRONMENT;

ANIMALS; DNA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLAMMATION; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649453054     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.06.002     Document Type: Review

References (119)

1. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
2. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
3. Chechlinska M., Kowalewska M., Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat. Rev. Cancer 2010, 10:2-3.
4. Shankar A., Wang J.J., Rochtchina E., Yu M.C., Kefford R., Mitchell P. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch. Intern. Med. 2006, 166:188-194.
5. Rasouli M., Okhovatian A., Enderami A. Serum proteins profile as an indicator of malignancy: multivariate logistic regression and ROC analyses. Clin. Chem. Lab. Med. 2005, 43:913-918.
6. Sengupta S., Lohse C.M., Cheville J.C., Leibovich B.C., Thompson R.H., Webster W.S., Frank I., Zincke H., Blute M.L., Kwon E.D. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 2006, 106:304-312.
7. Sierko E., Wojtukiewicz M.Z. Inhibition of platelet function: does it offer a chance of better cancer progression control?. Semin. Thromb. Hemost. 2007, 33:712-721.
8. Pedersen L.M., Milman N. Diagnostic significance of platelet count and other blood analyses in patients with lung cancer. Oncol. Rep. 2003, 10:213-216.
9. Sarraf K.M., Belcher E., Raevsky E., Nicholson A.G., Goldstraw P., Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2009, 137:425-428.
10. Cho H., Kim J.H. Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer. Biomarkers 2009, 14:161-170.
11. Neal C.P., Mann C.D., Sutton C.D., Garcea G., Ong S.L., Steward W.P., Dennison A.R., Berry D.P. Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur. J. Cancer 2009, 45:56-64.
12. Leitch E.F., Chakrabarti M., Crozier J.E., McKee R.F., Anderson J.H., Horgan P.G., McMillan D.C. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br. J. Cancer 2007, 97:1266-1270.
13. Shurin M.R., Lu L., Kalinski P., Stewart-Akers A.M., Lotze M.T. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immunopathol. 1999, 21:339-359.
14. Miyazaki K., Shimada K., Katabuchi H., Arakane F., Arao S., Okamura H. Activated (HLA-DR+) T-lymphocyte subsets in early epithelial ovarian cancer and malignant ovarian germ cell tumors. Gynecol. Oncol. 1995, 58:362-367.
15. Tsuyuguchi I., Shiratsuchi H., Fukuoka M. Increased circulating activated T-cells in lung cancer. Chest 1986, 89:705-708.
16. Ramanathan S., Gagnon J., Ilangumaran S. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer. Arch. Immunol. Ther. Exp. (Warsz.) 2008, 56:311-323.
17. Melichar B., Touskova M., Dvorak J., Jandik P., Kopecky O. The peripheral blood leukocyte phenotype in patients with breast cancer: effect of doxorubicin/paclitaxel combination chemotherapy. Immunopharmacol. Immunotoxicol. 2001, 23:163-173.
18. Sharma P., Sahni N.S., Tibshirani R., Skaane P., Urdal P., Berghagen H., Jensen M., Kristiansen L., Moen C., Sharma P., Zaka A., Arnes J., Sauer T., Akslen L.A., Schlichting E., Borresen-Dale A.L., Lonneborg A. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res. 2005, 7:R634-R644.
19. Chechlinska M., Kowalska M., Kaminska J. Cytokines as potential tumour markers. Expert Opin. Med. Diagn. 2008, 2:691-711.
20. Mumm J.B., Oft M. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 2008, 27:5913-5919.
21. Yasasever V., Camlica H., Duranyildiz D., Oguz H., Tas F., Dalay N. Macrophage migration inhibitory factor in cancer. Cancer Invest. 2007, 25:715-719.
22. Ramsey S., Lamb G.W., Aitchison M., McMillan D.C. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br. J. Cancer 2006, 95:1076-1080.
23. Heikkila K., Ebrahim S., Lawlor D.A. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J. Epidemiol. Community Health 2007, 61:824-833.
24. Malle E., Sodin-Semrl S., Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell. Mol. Life Sci. 2009, 66:9-26.
25. Lamb G.W., McMillan D.C., Ramsey S., Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br. J. Cancer 2006, 94:781-784.
26. Crozier J.E., McKee R.F., McArdle C.S., Angerson W.J., Anderson J.H., Horgan P.G., McMillan D.C. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br. J. Cancer 2006, 94:1833-1836.
27. Ishizuka M., Kita J., Shimoda M., Rokkaku K., Kato M., Sawada T., Kubota K. Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J. Surg. Oncol. 2009, 100:38-42.
28. Khandavilli S.D., Ceallaigh P.O., Lloyd C.J., Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009, 45:912-914.
29. Deans D.A., Wigmore S.J., de Beaux A.C., Paterson-Brown S., Garden O.J., Fearon K.C. Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br. J. Surg. 2007, 94:1501-1508.
30. Hilmy M., Campbell R., Bartlett J.M., McNicol A.M., Underwood M.A., McMillan D.C. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br. J. Cancer 2006, 95:1234-1238.
31. Moses A.G., Maingay J., Sangster K., Fearon K.C., Ross J.A. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. 2009, 21:1091-1095.
32. Al Murri A.M., Wilson C., Lannigan A., Doughty J.C., Angerson W.J., McArdle C.S., McMillan D.C. Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br. J. Cancer 2007, 96:891-895.
33. Pierce B.L., Ballard-Barbash R., Bernstein L., Baumgartner R.N., Neuhouser M.L., Wener M.H., Baumgartner K.B., Gilliland F.D., Sorensen B.E., McTiernan A., Ulrich C.M. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 2009, 27:3437-3444.
34. Kimura M., Tomita Y., Imai T., Saito T., Katagiri A., Ohara-Mikami Y., Matsudo T., Takahashi K. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 2001, 92:2072-2075.
35. Chan D.C., Chen C.J., Chu H.C., Chang W.K., Yu J.C., Chen Y.J., Wen L.L., Huang S.C., Ku C.H., Liu Y.C., Chen J.H. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann. Surg. Oncol. 2007, 14:84-93.
36. Shinriki S., Ueda M., Ota K., Nakamura M., Kudo M., Ibusuki M., Kim J., Yoshitake Y., Fukuma D., Jono H., Kuratsu J.I., Shinohara M., Ando Y. Aberrant expression of serum amyloid A in head and neck squamous cell carcinoma. J. Oral Pathol. Med. 2010, 39:41-47.
37. McMillan D.C. Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:223-226.
38. Zhong L., Coe S.P., Stromberg A.J., Khattar N.H., Jett J.R., Hirschowitz E.A. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J. Thorac. Oncol. 2006, 1:513-519.
39. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., Mehra R., Montie J.E., Pienta K.J., Sanda M.G., Kantoff P.W., Rubin M.A., Wei J.T., Ghosh D., Chinnaiyan A.M. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 2005, 353:1224-1235.
40. Hanas J.S., Hocker J.R., Cheung J.Y., Larabee J.L., Lerner M.R., Lightfoot S.A., Morgan D.L., Denson K.D., Prejeant K.C., Gusev Y., Smith B.J., Hanas R.J., Postier R.G., Brackett D.J. Biomarker identification in human pancreatic cancer sera. Pancreas 2008, 36:61-69.
41. Maciel C.M., Junqueira M., Paschoal M.E., Kawamura M.T., Duarte R.L., Carvalho Mda G., Domont G.B. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J. Exp. Ther. Oncol. 2005, 5:31-38.
42. Chen R., Brentnall T.A., Pan S., Cooke K., Moyes K.W., Lane Z., Crispin D.A., Goodlett D.R., Aebersold R., Bronner M.P. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell. Proteomics 2007, 6:1331-1342.
43. Seidel A., Brunner S., Seidel P., Fritz G.I., Herbarth O. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control. Br. J. Cancer 2006, 94:1726-1733.
44. Li H.Y., Wang S.M., Liu H.M., Li J., Han D., Bu S.S., Zhang M.Z. Analysis of modified nucleosides in the urine of patients with malignant cancer by liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:3161-3171.
45. Henneges C., Bullinger D., Fux R., Friese N., Seeger H., Neubauer H., Laufer S., Gleiter C.H., Schwab M., Zell A., Kammerer B. Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. BMC Cancer 2009, 9:104.
46. Tebib J.G., Reynaud C., Cedoz J.P., Letroublon M.C., Niveleau A. Relationship between urinary excretion of modified nucleosides and rheumatoid arthritis process. Br. J. Rheumatol. 1997, 36:990-995.
47. Yang J., Xu G., Zheng Y., Kong H., Pang T., Lv S., Yang Q. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2004, 813:59-65.
48. Issaq H.J., Nativ O., Waybright T., Luke B., Veenstra T.D., Issaq E.J., Kravstov A., Mullerad M. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 2008, 179:2422-2426.
49. Chan K.C., Lo Y.M. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br. J. Cancer 2007, 96:681-685.
50. Banki F., Yacoub W.N., Hagen J.A., Mason R.J., Ayazi S., DeMeester S.R., Lipham J.C., Danenberg K., Danenberg P., DeMeester T.R. Plasma DNA is more reliable than carcinoembryonic antigen for diagnosis of recurrent esophageal cancer. J. Am. Coll. Surg. 2008, 207:30-35.
51. Paci M., Maramotti S., Bellesia E., Formisano D., Albertazzi L., Ricchetti T., Ferrari G., Annessi V., Lasagni D., Carbonelli C., De Franco S., Brini M., Sgarbi G., Lodi R. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 2009, 64:92-97.
52. Steinman C.R. Circulating DNA in polyarteritis nodosa and related syndromes. Arthritis Rheum. 1982, 25:1425-1430.
53. Vargo J.S., Becker D.M., Philbrick J.T., Schoonover F.W., Davis J.S. Plasma DNA. A simple, rapid test for aiding the diagnosis of pulmonary embolism. Chest 1990, 97:63-68.
54. Kocsis A.K., Szabolcs A., Hofner P., Takacs T., Farkas G., Boda K., Mandi Y. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology 2009, 9:383-391.
55. Shin C., Kim J.K., Kim J.H., Jung K.H., Cho K.J., Lee C.K., Lee S.G. Increased cell-free DNA concentrations in patients with obstructive sleep apnea. Psychiatry Clin. Neurosci. 2008, 62:721-727.
56. Fatouros I.G., Destouni A., Margonis K., Jamurtas A.Z., Vrettou C., Kouretas D., Mastorakos G., Mitrakou A., Taxildaris K., Kanavakis E., Papassotiriou I. Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. Clin. Chem. 2006, 52:1820-1824.
57. van der Drift M.A., Prinsen C.F., Hol B.E., Bolijn A.S., Jeunink M.A., Dekhuijzen P.N., Thunnissen F.B. Can free DNA be detected in sputum of lung cancer patients?. Lung Cancer 2008, 61:385-390.
58. Miura N., Kanamori Y., Takahashi M., Sato R., Tsukamoto T., Takahashi S., Harada T., Sano A., Shomori K., Harada T., Kigawa J., Ito H., Terakawa N., Hasegawa J., Shiota G. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Oncol. Rep. 2007, 17:541-548.
59. Tani N., Ichikawa D., Ikoma D., Tomita H., Sai S., Ikoma H., Okamoto K., Ochiai T., Ueda Y., Otsuji E., Yamagishi H., Miura N., Shiota G. Circulating cell-free mRNA in plasma as a tumor marker for patients with primary and recurrent gastric cancer. Anticancer Res. 2007, 27:1207-1212.
60. Dasi F., Martinez-Rodes P., March J.A., Santamaria J., Martinez-Javaloyas J.M., Gil M., Alino S.F. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann. N. Y. Acad. Sci. 2006, 1075:204-210.
61. Miura N., Nakamura H., Sato R., Tsukamoto T., Harada T., Takahashi S., Adachi Y., Shomori K., Sano A., Kishimoto Y., Ito H., Hasegawa J., Shiota G. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci. 2006, 97:1366-1373.
62. Bodnar A.G., Kim N.W., Effros R.B., Chiu C.P. Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 1996, 228:58-64.
63. Ellinger J., Albers P., Perabo F.G., Muller S.C., von Ruecker A., Bastian P.J. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J. Urol. 2009, 182:324-329.
64. Altimari A., Grigioni A.D., Benedettini E., Gabusi E., Schiavina R., Martinelli A., Morselli-Labate A.M., Martorana G., Grigioni W.F., Fiorentino M. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am. J. Clin. Pathol. 2008, 129:756-762.
65. Kolesnikova E.V., Tamkovich S.N., Bryzgunova O.E., Shelestyuk P.I., Permyakova V.I., Vlassov V.V., Tuzikov A.S., Laktionov P.P., Rykova E.Y. Circulating DNA in the blood of gastric cancer patients. Ann. N. Y. Acad. Sci. 2008, 1137:226-231.
66. Skvortsova T.E., Rykova E.Y., Tamkovich S.N., Bryzgunova O.E., Starikov A.V., Kuznetsova N.P., Vlassov V.V., Laktionov P.P. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer 2006, 94:1492-1495.
67. Sharma P., Kumar J., Garg G., Kumar A., Patowary A., Karthikeyan G., Ramakrishnan L., Brahmachari V., Sengupta S. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell. Biol. 2008, 27:357-365.
68. Stenvinkel P., Karimi M., Johansson S., Axelsson J., Suliman M., Lindholm B., Heimburger O., Barany P., Alvestrand A., Nordfors L., Qureshi A.R., Ekstrom T.J., Schalling M. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease?. J. Intern. Med. 2007, 261:488-499.
69. Duffy M.J., Napieralski R., Martens J.W., Span P.N., Spyratos F., Sweep F.C., Brunner N., Foekens J.A., Schmitt M. EORTC PathoBiology Group, Methylated genes as new cancer biomarkers. Eur. J. Cancer 2009, 45:335-346.
70. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 2009, 6:339-351.
71. Mostert B., Sleijfer S., Foekens J.A., Gratama J.W. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat. Rev. 2009, 35:463-474.
72. Van der Auwera I., Elst H.J., Van Laere S.J., Maes H., Huget P., van Dam P., Van Marck E.A., Vermeulen P.B., Dirix L.Y. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br. J. Cancer 2009, 100:1277-1286.
73. Ikeda S., Funakoshi N., Usui S., Takiguchi N., Hiranuma S., Shibata T. Prognostic significance of gastric cancer metastasis in second-tier lymph nodes detected on reverse transcriptase-polymerase chain reaction and immunohistochemistry. Pathol. Int. 2008, 58:45-50.
74. Farmen R.K., Nordgard O., Gilje B., Shammas F.V., Kvaloy J.T., Oltedal S., Heikkila R. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients. Breast Cancer Res. Treat. 2008, 108:251-258.
75. Nordgard O., Oltedal S., Korner H., Aasprong O.G., Tjensvoll K., Gilje B., Heikkila R. Quantitative RT-PCR detection of tumor cells in sentinel lymph nodes isolated from colon cancer patients with an ex vivo approach. Ann. Surg. 2009, 249:602-607.
76. Tamura N., Iinuma H., Takada T. Prospective study of the quantitative carcinoembryonic antigen and cytokeratin 20 mRNA detection in peritoneal washes to predict peritoneal recurrence in gastric carcinoma patients. Oncol. Rep. 2007, 17:667-672.
77. Guo B., Luo C., Xun C., Xie J., Wu X., Pu J. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR. Exp. Oncol. 2009, 31:43-47.
78. D'Armento G., Daniele L., Mariani S., Ottaviani D., Mussa A., Cassoni P., Sapino A., Bussolati G. Added value of combined gene and protein expression of CK20 and CEA in non-macroscopically involved lymph nodes of colorectal cancer. Int. J. Surg. Pathol. 2009, 17:93-98.
79. Setoyama T., Natsugoe S., Okumura H., Matsumoto M., Uchikado Y., Aikou T. Isolated tumour cells in blood and E-cadherin expression in oesophageal squamous cell cancer. Br. J. Surg. 2007, 94:984-991.
80. Denninghoff V., Allende D., Paesani F., Garcia A., Avagnina A., Perazzo F., Abalo E., Crimi G., Elsner B. Sentinel lymph node molecular pathology in breast carcinoma. Diagn. Mol. Pathol. 2008, 17:214-219.
81. Ntoulia M., Stathopoulou A., Ignatiadis M., Malamos N., Mavroudis D., Georgoulias V., Lianidou E.S. Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin. Biochem. 2006, 39:879-887.
82. Roncella S., Ferro P., Bacigalupo B., Dessanti P., Pronzato P., Franceschini M.C., Prattico L., Carletti A.M., Canessa P.A., Fontana V., Fais F., Pistillo M.P., Fedeli F. Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions. Diagn. Mol. Pathol. 2008, 17:28-33.
83. Dono M., Ferro P., Benedetti L., Capellini C., Moroni M., Dessanti P., Bacigalupo B., Tartaglione A., Battolla E., Fedeli F., Roncella S. Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis. J. Neurooncol. 2009, 91:295-298.
84. Ferrucci P.F., Rabascio C., Gigli F., Corsini C., Giordano G., Bertolini F., Martinelli G. A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int. J. Oncol. 2007, 30:955-962.
85. Lambrechts A.C., Bosma A.J., Klaver S.G., Top B., Perebolte L., van' t Veer L.J., Rodenhuis S. Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res. Treat. 1999, 56:219-231.
86. Krismann M., Todt B., Schroder J., Gareis D., Muller K.M., Seeber S., Schutte J. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J. Clin. Oncol. 1995, 13:2769-2775.
87. Fava T.A., Desnoyers R., Schulz S., Park J., Weinberg D., Mitchell E., Waldman S.A. Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. J. Clin. Oncol. 2001, 19:3951-3959.
88. You F., Roberts L.A., Kang S.P., Nunes R.A., Dias C., Iglehart J.D., Solomon N.A., Friedman P.N., Harris L.N. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. J. Hematol. Oncol. 2008, 1:2.
89. Grunewald K., Haun M., Urbanek M., Fiegl M., Muller-Holzner E., Gunsilius E., Dunser M., Marth C., Gastl G. Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab. Invest. 2000, 80:1071-1077.
90. Bostick P.J., Chatterjee S., Chi D.D., Huynh K.T., Giuliano A.E., Cote R., Hoon D.S. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J. Clin. Oncol. 1998, 16:2632-2640.
91. Ko Y., Grunewald E., Totzke G., Klinz M., Fronhoffs S., Gouni-Berthold I., Sachinidis A., Vetter H. High percentage of false-positive results of cytokeratin 19 RT-PCR in blood: a model for the analysis of illegitimate gene expression. Oncology 2000, 59:81-88.
92. Jung R., Petersen K., Kruger W., Wolf M., Wagener C., Zander A., Neumaier M. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br. J. Cancer 1999, 81:870-873.
93. Vlems F.A., Diepstra J.H., Cornelissen I.M., Ruers T.J., Ligtenberg M.J., Punt C.J., van Krieken J.H., Wobbes T., van Muijen G.N. Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue. Mol. Pathol. 2002, 55:156-163.
94. Merrie A.E., Yun K., Gunn J., Phillips L.V., McCall J.L. Analysis of potential markers for detection of submicroscopic lymph node metastases in breast cancer. Br. J. Cancer 1999, 80:2019-2024.
95. Hamakawa H., Fukuzumi M., Bao Y., Sumida T., Kayahara H., Onishi A., Sogawa K. Keratin mRNA for detecting micrometastasis in cervical lymph nodes of oral cancer. Cancer Lett. 2000, 160:115-123.
96. Corradini P., Voena C., Astolfi M., Delloro S., Pilotti S., Arrigoni G., Bregni M., Pileri A., Gianni A.M. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann. Oncol. 2001, 12:1693-1698.
97. Zippelius A., Kufer P., Honold G., Kollermann M.W., Oberneder R., Schlimok G., Riethmuller G., Pantel K. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J. Clin. Oncol. 1997, 15:2701-2708.
98. Broll R., Weschta M., Windhoevel U., Berndt S., Schwandner O., Roblick U., Schiedeck T.H., Schimmelpenning H., Bruch H.P., Duchrow M. Prognostic significance of free gastrointestinal tumor cells in peritoneal lavage detected by immunocytochemistry and polymerase chain reaction. Langenbecks Arch. Surg. 2001, 386:285-292.
99. Jung R., Kruger W., Hosch S., Holweg M., Kroger N., Gutensohn K., Wagener C., Neumaier M., Zander A.R. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br. J. Cancer 1998, 78:1194-1198.
100. Pitini V., Arrigo C., Amata C., La Torre I. Limitations of molecular detection of CK19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically negative axillary lymph nodes. Ann. Oncol. 2005, 16:1845.
101. Kowalewska M., Chechlinska M., Markowicz S., Kober P., Nowak R. The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur. J. Cancer 2006, 42:2671-2674.
102. Goeminne J.C., Guillaume T., Salmon M., Machiels J.P., D'Hondt V., Symann M. Unreliability of carcinoembryonic antigen (CEA) reverse transcriptase-polymerase chain reaction (RT-PCR) in detecting contaminating breast cancer cells in peripheral blood stem cells due to induction of CEA by growth factors. Bone Marrow Transplant. 1999, 24:769-775.
103. Kruger W.H., Jung R., Detlefsen B., Mumme S., Badbaran A., Brandner J., Renges H., Kroger N., Zander A.R. Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells. Med. Oncol. 2001, 18:33-38.
104. Ballestrero A., Garuti A., Bertolotto M., Rocco I., Boy D., Nencioni A., Ottonello L., Patrone F. Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer. Br. J. Cancer 2005, 92:1948-1952.
105. Stathopoulos E.N., Sanidas E., Kafousi M., Mavroudis D., Askoxylakis J., Bozionelou V., Perraki M., Tsiftsis D., Georgoulias V. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann. Oncol. 2005, 16:240-246.
106. Stathopoulou A., Ntoulia M., Perraki M., Apostolaki S., Mavroudis D., Malamos N., Georgoulias V., Lianidou E.S. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int. J. Cancer 2006, 119:1654-1659.
107. Revillion F., Lhotellier V., Hornez L., Leroy A., Baranzelli M.C., Giard S., Bonneterre J., Peyrat J.P. Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. Int. J. Biol. Markers 2008, 23:10-17.
108. Tjensvoll K., Gilje B., Oltedal S., Shammas V.F., Kvaloy J.T., Heikkila R., Nordgard O. A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow. Breast Cancer Res. Treat. 2009, 116:329-338.
109. Ishigami S., Sakamoto A., Uenosono Y., Nakajo A., Okumura H., Matsumoto M., Setoyama T., Arigami T., Uchikado Y., Arima H., Natsugoe S., Aikou T. Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer. J. Surg. Res. 2008, 148:205-209.
110. Dimmler A., Gerhards R., Betz C., Gunther K., Reingruber B., Horbach T., Baumann I., Kirchner T., Hohenberger W., Papadopoulos T. Transcription of cytokeratins 8, 18, and 19 in bone marrow and limited expression of cytokeratins 7 and 20 by carcinoma cells: inherent limitations for RT-PCR in the detection of isolated tumor cells. Lab. Invest. 2001, 81:1351-1361.
111. Koga Y., Yasunaga M., Moriya Y., Akasu T., Fujita S., Yamamoto S., Kozu T., Baba H., Matsumura Y. Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci. 2008, 99:1977-1983.
112. Suchy B., Austrup F., Driesel G., Eder C., Kusiak I., Uciechowski P., Grill H.J., Giesing M. Detection of mammaglobin expressing cells in blood of breast cancer patients. Cancer Lett. 2000, 158:171-178.
113. Liu Z., Jiang M., Yan F., Xu L., Zhao J., Ju H. Multipoint quantification of multimarker genes in peripheral blood and micrometastasis characteristic in peri-operative esophageal cancer patients. Cancer Lett. 2008, 261:46-54.
114. Aerts J., Wynendaele W., Paridaens R., Christiaens M.R., van den Bogaert W., van Oosterom A.T., Vandekerckhove F. A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann. Oncol. 2001, 12:39-46.
115. Mikhitarian K., Martin R.H., Ruppel M.B., Gillanders W.E., Hoda R., Schutte del H., Callahan K., Mitas M., Cole D.J. Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer 2008, 8:55.
116. Liu L., Liao G.Q., He P., Zhu H., Liu P.H., Qu Y.M., Song X.M., Xu Q.W., Gao Q., Zhang Y., Chen W.F., Yin Y.H. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem. Biophys. Res. Commun. 2008, 372:756-760.
117. Schuster R., Max N., Mann B., Heufelder K., Thilo F., Grone J., Rokos F., Buhr H.J., Thiel E., Keilholz U. Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int. J. Cancer 2004, 108:219-227.
118. Cheng M., Chen Y., Yu X., Tian Z., Wei H. Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer 2008, 8:156.
119. Kojima T., Hashimoto Y., Watanabe Y., Kagawa S., Uno F., Kuroda S., Tazawa H., Kyo S., Mizuguchi H., Urata Y., Tanaka N., Fujiwara T. A simple biological imaging system for detecting viable human circulating tumor cells. J. Clin. Invest. 2009, 119:3172-3181.